Envestnet Asset Management Inc. lowered its stake in MEDNAX Inc (NYSE:MD) by 36.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 31,376 shares of the company’s stock after selling 18,214 shares during the quarter. Envestnet Asset Management Inc.’s holdings in MEDNAX were worth $1,727,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Pzena Investment Management LLC grew its stake in shares of MEDNAX by 134.8% in the 1st quarter. Pzena Investment Management LLC now owns 2,258,712 shares of the company’s stock worth $125,652,000 after buying an additional 1,296,682 shares during the last quarter. Earnest Partners LLC grew its stake in shares of MEDNAX by 48.1% in the 4th quarter. Earnest Partners LLC now owns 2,212,691 shares of the company’s stock worth $118,246,000 after buying an additional 718,317 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in shares of MEDNAX by 6.8% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,515,288 shares of the company’s stock worth $80,977,000 after buying an additional 96,005 shares during the last quarter. HealthCor Management L.P. purchased a new stake in shares of MEDNAX in the 4th quarter worth approximately $67,421,000. Finally, Wells Fargo & Company MN grew its stake in shares of MEDNAX by 0.6% in the 1st quarter. Wells Fargo & Company MN now owns 843,529 shares of the company’s stock worth $46,926,000 after buying an additional 4,647 shares during the last quarter. Institutional investors own 97.14% of the company’s stock.

Several analysts recently weighed in on the company. TheStreet upgraded MEDNAX from a “c+” rating to a “b” rating in a research note on Monday, March 12th. Jefferies Group set a $58.00 price target on MEDNAX and gave the stock a “hold” rating in a research note on Thursday, March 15th. Zacks Investment Research downgraded MEDNAX from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 21st. Credit Suisse Group assumed coverage on MEDNAX in a research note on Tuesday, March 27th. They issued a “neutral” rating and a $57.00 price target on the stock. Finally, Robert W. Baird upped their price target on MEDNAX from $48.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $55.92.

In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $58.35, for a total transaction of $175,050.00. Following the sale, the insider now directly owns 39,716 shares in the company, valued at approximately $2,317,428.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.40% of the company’s stock.

Shares of MD opened at $45.85 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.63. MEDNAX Inc has a 12 month low of $40.56 and a 12 month high of $63.04. The firm has a market cap of $4.37 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.18 and a beta of 0.26.

MEDNAX (NYSE:MD) last issued its earnings results on Monday, April 30th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. MEDNAX had a return on equity of 10.13% and a net margin of 9.34%. The business had revenue of $901.90 million for the quarter, compared to the consensus estimate of $903.75 million. During the same period last year, the business posted $0.75 EPS. The company’s revenue was up 7.9% compared to the same quarter last year. equities research analysts expect that MEDNAX Inc will post 3.94 earnings per share for the current year.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.